



IMPORTANT NOTICE

Route to:
 Office Manager
 Medical Staff
 Nursing Staff
 Immunization
Coordinator

An Immunization Update from the Idaho Immunization Program (IIP)

VACCINE SUPPLY UPDATE

MenHibrix® (Hib-MenCY-TT) Vaccine

The IIP currently has MenHibrix® (Hib-MenCY-TT) vaccine available to use as recommended by the Advisory Committee on Immunization Practices (ACIP). The vaccine must be ordered by completing the IIP MenHibrix® Order Form (see attached). Orders will be processed and distributed in single dose increments. Please review the recommendations and guidance below:

ACIP Recommendations: Infants at increased risk for meningococcal disease should be vaccinated with a 4-dose series of Hib-MenCY-TT. These include infants with recognized persistent complement pathway deficiencies and infants who have anatomic or functional asplenia including sickle cell disease. Additionally, Hib-MenCY-TT can be used in infants aged 6 weeks through 18 months who are in communities with serogroups C and Y meningococcal disease outbreaks, but Hib-MenCY-TT is not adequate for infants traveling to the Hajj or the "meningitis belt" of sub-Saharan Africa (a quadrivalent meningococcal vaccine that contains serogroups A and W135 is required for those infants and may be given starting at age 9 months).

If an infant at increased risk for meningococcal disease is behind on his or her Hib vaccine doses, Hib-MenCY-TT may be used following the same catch-up schedule used for Hib vaccine. However, if the first dose of Hib-MenCY-TT is given at or after 12 months of life, 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease. For infants at increased risk for meningococcal disease who have received or are going to receive a different Hib vaccine product, ACIP recommends a 2-dose series of MenACWY-D if they are aged 9 through 23 months or either of the two quadrivalent meningococcal vaccine products after age 23 months.

Hib-MenCY-TT may be co-administered with other routine infant vaccinations, including 13-valent pneumococcal conjugate vaccine. Hib-MenCY-TT should not be co-administered with other Hib-containing vaccines.

Guidance for Use: Based on an assessment of the potential public health impact, including the current low incidence of meningococcal disease in the United States, at this time ACIP does not recommend routine meningococcal vaccination for infants who are not at increased risk for meningococcal disease. Hib-MenCY-TT is safe and immunogenic against Hib and *N. meningitidis* serogroups C and Y. Hib-MenCY-TT may be used in any infant for routine vaccination against Hib and will offer some protection against serogroups C and Y meningococcal disease. Four doses of Hib-MenCY-TT fulfill the primary series and booster dose Hib immunization recommendations. If Hib-MenCY-TT vaccine is used to achieve

February 7, 2014



IMPORTANT NOTICE

An Immunization Update from the Idaho Immunization Program (IIP)

protection against serogroups C and Y, Hib-MenCY-TT should be used for all 4 doses of Hib vaccine. Because the protection offered by meningococcal vaccines wanes over time, an infant series will be unlikely to provide persistent protection against meningococcal disease until age 11–12 years, the age of recommended adolescent vaccination. Infants and children who received Hib-MenCY-TT and are travelling to areas with high endemic rates of meningococcal disease such as the "meningitis belt" are not protected against serogroups A and W-135 and should receive a quadrivalent meningococcal conjugate vaccine licensed for children aged ≥9 months before travel. "

For additional about infant meningococcal vaccination recommendations go to <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm>.

Pentacel® (DTaP-IPV-HIB)

Pentacel® (DTaP-IPV-HIB) is currently available to order in limited quantities. Supply is expected to increase throughout the year. If your office has been using Pediarix® (DTaP-IPV-Hep B) during the shortage and would like to transition back to Pentacel®, then please remember your current vaccine supply must still be used.

Prevnar 13™ (PCV13)

Pfizer began shipping new packaging of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine) in December 2013. The new packaging is a result of packaging standardization and includes changes to the size of the package and the style of the pre-filled syringe label. The Prevnar 13™ formulation has not changed. The new carton is slightly larger, the informational leaflet will now sit on top of the tray, and the lot number and expiration date are on the clear area of the syringe.

February 7, 2014

IMMUNIZATION REMINDER INFORMATION SYSTEM (IRIS)

Vaccine Management

Vaccine orders should **NOT** be entered **manually** into an organization's vaccine **inventory**. All orders and transfers should be accepted through the manage transfers screen. In addition, when accepting vaccine orders and transfers with lot numbers already existing in the inventory, always *Merge with Existing Lot*.

Transfer Vaccine Item					
Transfer Quantity	Vaccine Group	Trade Name	Lot Number	Inventory Action	Shipping Information
20	MMR	MMR II	1025AA	Merge with Existing Lot	

Do not create a new lot. Creating a new lot will cause the lot number to be listed multiple times in the inventory. Creating multiple lots will also cause errors for offices that export information into IRIS from Electronic Health Records systems.



IMPORTANT NOTICE

An Immunization Update from the Idaho Immunization Program (IIP)

Username and Password Request/Reset

As a reminder, all requests for IRIS accounts, passwords, and password resets must be submitted online. Requests will not be processed over the phone. Go to the [IRIS login](#) page for additional information.

STORAGE AND HANDLING

Temperature Recorder Recalibration

The TR-52i temperature recording devices supplied and installed by the IIP will need to be recalibrated and certified. The IIP is currently responsible for the recalibration and certification of the TR-52i. Over the next several months the IIP will visit each provider's office, remove the TR-52i currently installed, download the temperatures, and install a recalibrated, currently certified TR-52i.

Each month a different district or group of providers will receive a visit. Before the visit your office will receive a fax notification, an announcement will be posted in IRIS, and an IIP staff member will call your office. Current recalibration is being conducted in Central and Southwest Idaho.

Temperature Monitoring and Recording in a New Storage Unit

When your office gets a new vaccine storage unit or moves a vaccine storage unit from another location, temperatures should be monitored for stability before vaccines are stored in the unit. Many storage units have guidance indicating how many days a unit should be plugged in before use. The IIP recommends that storage units are plugged in for 48 hours before temperatures are monitored. After the 48 hours, temperatures should be monitored for 5 days. After 5 days of stable temperatures (within the required range for vaccine storage) have been recorded, vaccine may be stored in the unit. While the IIP does not require the temperatures be submitted for review, the temperatures must be available if requested by an IIP staff member.

February 7, 2014

SHOT SMARTS – SAVE THE DATE

Be sure to save the date for Shot Smarts 2014. Registration will open soon.

City	Day	Date
Pocatello	Tuesday	April 29, 2014
Boise	Wednesday	April 30, 2014
Post Falls	Friday	May 2, 2014

MenHibrix® Order Form

MenHibrix® (Hib-MenCY-TT) vaccine is currently available from the Idaho Immunization Program in limited quantities and only to infants at increased risk for meningococcal disease, which includes:

- Infants with recognized persistent complement pathway deficiencies, and
- Infants who have anatomic or functional asplenia including sickle cell disease.

Please note that the MenHibrix® vaccine does not meet the requirement for international travel to the “meningitis belt,” and the quadrivalent MCV4 vaccine should be used to meet that requirement.

Based on an assessment of the potential public health impact, including the current low incidence of meningococcal disease in the United States, at this time Advisory Committee on Immunization Practices (ACIP) does not recommend routine meningococcal vaccination for infants who are *not* at increased risk for meningococcal disease (for additional information go to <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm>).

MenHibrix® is currently available in single dose distribution only. MenHibrix® is part of a four-dose series for infants aged 6 weeks through 18 months of age, and replaces the Hib vaccine.

This order form is for MenHibrix® vaccine only. If you would like to place an order for additional vaccine or vaccines other than MenHibrix®, then please do so by logging into Idaho’s Immunization Reminder Information System (IRIS).

To place an order for MenHibrix® please complete and return this form to the Idaho Immunization Program (IIP) by fax (208.334.4914), email (IIP@dhw.idaho.gov), or standard mail (see address below).

Organization Name: _____ VFC Pin: _____

Ordered by: _____ Date: _____

Please indicate which high-risk condition below is applicable to the patient:

- Persistent complement pathway deficiency
- Anatomic or functional asplenia

Patient’s Date of Birth: ____ / ____ / ____
 MM DD YYYY

Circle the dose number in the series that you are ordering: 1 2 3 4

Please indicate the eligibility of the patient. If the patient is eligible for the federal Vaccines for Children (VFC) program, then please include which criteria is met:

- Not VFC-eligible
- VFC-eligible
 - Is a Native American or Alaska Native,
 - Is enrolled in Medicaid,
 - Has no health insurance, or
 - Is underinsured (has health insurance, but the coverage does not include vaccine; eligible at a Federally Qualified Health Center (FQHC), Rural Health Clinic (RHC), or local public health department).

Physician Name (please print): _____

Physician Signature: _____ Date: _____

